Search

Your search keyword '"Chapple, C. R."' showing total 548 results
Start Over Author "Chapple, C. R."
548 results on '"Chapple, C. R."'

103. BMX Bike Injuries

Author

Sparnon, Anthony, Adlam, David M., Tuck, Jonathan S., and Chapple, C. R.

Published
1984

109. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS

Author

Sexton, Chris C., Coyne, Karin S., Kopp, Zoe S., Irwin, D. E., Ian, Milsom, Aiyer, Lalitha P., Tubaro, Andrea, Chapple, C. R., Wein, Alan J., and Epiluts, Team

Subjects
Adult, Male, Stress incontinence, medicine.medical_specialty, oab, Urology, prevalence, MEDLINE, urologic and male genital diseases, Severity of Illness Index, Quality of life, bother, bph, Surveys and Questionnaires, luts, Severity of illness, medicine, Nocturia, Humans, Aged, Gynecology, Descriptive statistics, Urinary symptoms, Treatment seeking, business.industry, Middle Aged, Patient Acceptance of Health Care, treatment seeking, medicine.disease, Urination Disorders, United States, Europe, Physical therapy, Quality of Life, Female, medicine.symptom, business, Epidemiologic Methods
Abstract

OBJECTIVE To assess the (i) the overlap between voiding, storage, and postmicturition symptoms; and (ii) the relative effect of bother and implications for treatment seeking within these symptom groups, using data from the EpiLUTS study. SUBJECTS AND METHODS This cross-sectional population-representative survey was conducted via the Internet in the USA, the UK and Sweden. Participants were asked to rate the frequency and symptom-specific bother of individual LUTS. Descriptive statistics were used to examine differences in International Continence Society LUTS subgroups. Logistc regressions were used with treatment seeking as the dependent variable and the bother of individual symptoms as predictors. RESULTS The survey response rate was 59%. The sample included 30 000 participants (14 139 men and 15 861 women); 71% of men and 75% of women reported at least one LUTS, and about half reported LUTS from more than one symptom group. Rates of bother were greatest for those who reported multiple storage, voiding and postmicturition LUTS (men 83%, women 89%). Less than a third of participants with LUTS from all three groups reported seeking treatment. Consistent correlates of treatment seeking across genders included bother due to weak stream, incomplete emptying, perceived daytime frequency, nocturia and urgency. There were also significant associations for several types of incontinence, most commonly stress incontinence in women and leaking during sexual activity in men. Despite high rates of symptom overlap and symptom-specific bother, few participants sought treatment for LUTS. CONCLUSION Common conditions such as BPH and OAB are treatable, and clinicians should proactively ask patients about urinary symptoms. Given the many types of LUTS that patients experience, it is imperative that clinicians assess all LUTS to ensure that appropriate treatments are prescribed.

Published
2009

112. Safety and tolerability of the β 3 ‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial

Author

Nitti, V. W., primary, Chapple, C. R., additional, Walters, C., additional, Blauwet, M. B., additional, Herschorn, S., additional, Milsom, I., additional, Auerbach, S., additional, and Radziszewski, P., additional

Published
2014
Full Text
View/download PDF

122. Failure of Urinary Drainage: Lower Tract.

Author

Hohenfellner, Markus, Santucci, Richard A., Patterson, J. M., and Chapple, C. R.

Abstract

Failure of the lower urinary tract to drain adequately is one of the most common presenting emergencies seen by the practicing urologist. The wide variety of pathologies that can cause this problem needs to be taken into account when assessing the patient, as it is important not to subject the patient to undue risks. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

127. Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.

Author

Nitti, V. W., Chapple, C. R., Walters, C., Blauwet, M. B., Herschorn, S., Milsom, I., Auerbach, S., and Radziszewski, P.

Abstract

Aims To evaluate the safety and tolerability of the β3-adrenoceptor agonist, mirabegron, in patients with overactive bladder (OAB). Methods Tolerability and safety data from three 12-week, randomised, placebo-controlled, double-blind, Phase III trials (Studies 046, 047 and 074) were pooled by treatment group. The three studies were of a similar design, although the assessed doses of mirabegron [25, 50 or 100 mg once daily (qd)] varied, and tolterodine extended release (ER) 4 mg was included as an active-control arm in Study 046 only. Tolerability and safety data from a 1-year, randomised, double-blind, Phase III trial (Study 049) are also presented. Safety variables included the incidence and severity of treatment-emergent adverse events (TEAEs), vital signs and electrocardiogram data. Results Mirabegron (25, 50 or 100 mg qd) was safe and well-tolerated in patients with OAB over 12-week ( n = 2736) and 1-year ( n = 1632) periods. The incidence of TEAEs and treatment discontinuations as a result of TEAEs was low; the majority were mild in severity and few were serious. Hypertension, nasopharyngitis and urinary tract infection were the most common TEAEs with mirabegron. The mirabegron tolerability profile was similar to that seen with placebo and tolterodine ER 4 mg, except for dry mouth, which occurred, on average, five times less frequently with mirabegron than tolterodine ER 4 mg. In the pooled 12-week analysis, mirabegron 50 mg was associated with placebo-adjusted mean increases of 0.4-0.6 mmHg in blood pressure and approximately one beat per minute in pulse rate, both reversible upon treatment discontinuation. The incidence of Major Adverse Cardiovascular Events as adjudicated by an independent cardiovascular committee was low and similar across treatment groups. Conclusion The favourable tolerability profile of mirabegron in patients with OAB may allow improved treatment compliance compared with antimuscarinics, with important implications for patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

128. In vitroα1‐adrenoceptor pharmacology of Ro 70–0004 and RS‐100329, novel α1A‐adrenoceptor selective antagonists

Author

Williams, T J, primary, Blue, D R, additional, Daniels, D V, additional, Davis, B, additional, Elworthy, T, additional, Gever, J R, additional, Kava, M S, additional, Morgans, D, additional, Padilla, F, additional, Tassa, S, additional, Vimont, R L, additional, Chapple, C R, additional, Chess‐Williams, R, additional, Eglen, R M, additional, Clarke, D E, additional, and Ford, A P D W, additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results